Entasis Therapeutics

About:

Entasis Therapeutics is developing a portfolio of innovative cures.

Twitter/X: entasistx

Top Investors: TPG, Sofinnova Investments, Novo Holdings, Frazier Healthcare Partners, Pivotal bioVenture Partners

Description:

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Entasis’ anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), and zoliflodacin (targeting Neisseria gonorrhoeae).

Total Funding Amount:

$200M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Waltham, Massachusetts, United States

Founded Date:

2015-01-01

Contact Email:

rachel.lewis(AT)entasistx.com

Founders:

Manoussos Perros

Number of Employees:

51-100

Last Funding Date:

2021-05-03

IPO Status:

Delisted

Industries: